Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors

Journal of Immunology

Volumn 176, Issue 10, 2006, Pages 6302-6312

  Khan, Tahira ^a   Stauffer, Jimmy K ^a   Williams, Rebecca ^a   Hixon, Julie A ^a   Salcedo, Rosalba ^b   Lincoln, Erin ^b   Back, Timothy C ^b   Powell, Douglas ^a   Lockett, Stephen ^b   Arnold, Alma C ^b   Sayers, Thomas J ^b   Wigginton, Jon M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN BID; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CELL CYCLE; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SENSITIZATION;

EID: 33646472266     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.10.6302     Document Type: Article

References (58)

1. Iolascon, A., A. Borriello, L. Giordani, V. Cucciolla, A. Moretti, F. Monno, V. Criniti, A. Marzullo, M. Criscuolo, and F. D. Ragione. 2003. Caspase 3 and 8 deficiency in human neuroblastoma. Cancer Genet. Cytogenet. 146: 41-47.
2. Teitz, T., T. Wei, M. B. Valentine, E. F. Vanin, J. Grenet, V. A. Valentine, F. G. Behm, A. T. Look, J. M. Lahti, and V. J. Kidd. 2000. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat. Med. 6: 529-535.
3. Bernassola, F., C. Scheuerpflug, I. Herr, P. H. Krammer, K. M. Debatin, and G. Melino. 1999. Induction of apoptosis by IFN-γ in human neuroblastoma cell lines through the CD95/CD95L autocrine circuit. Cell Death Differ. 6: 652-660.
4. Yang, X., M. S. Merchant, M. E. Romero, M. Tsokos, L. H. Wexler, U. Kontny, C. L. Mackall, and C. J. Thiele. 2003. Induction of caspase 8 by interferon-γ renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB. Cancer Res. 63: 1122-1129.
5. Poulaki, V., N. Mitsiades, M. E. Romero, and M. Tsokos. 2001. Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and Bcl-2. Cancer Res. 61: 4864-4872.
6. Azuhata, T., D. Scott, S. Takamizawa, J. Wen, A. Davidoff, M. Fukuzawa, and A. Sandler. 2001. The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma. J. Pediatr. Surg. 36: 1785-1791.
7. Emran, M. A., A. Rebbaa, and B. L. Mirkin. 2002. Doxorubicin resistant neuroblastoma cells secrete factors that activate AKT and attenuate cytotoxicity in drug-sensitive cells. Cancer Lett. 182: 53-59.
8. Yin, D., H. Zhou, T. Kumagai, G. Liu, J. M. Ong, K. L. Black, and H. P. Koeffler. 2005. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 24: 344-354.
9. King, R. W., R. J. Deshaies, J. M. Peters, and M. W. Kirschner. 1996. How proteolysis drives the cell cycle. Science 274: 1652-1659.
10. Adams, J. 2004. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5: 417-421.
11. Hideshima, T., P. Richardson, D. Chauhan, V. J. Palombella, P. J. Elliott, J. Adams, and K. C. Anderson. 2001. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61: 3071-3076.
12. Kane, R. C., P. F. Bross, A. T. Farrell, and R. Pazdur. 2003. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8: 508-513.
13. Shinohara, K., M. Tomioka, H. Nakano, S. Tone, H. Ito, and S. Kawashima. 1996. Apoptosis induction resulting from proteasome inhibition. Biochem. J. 317 (Pt 2): 385-388.
14. Herrmann, J. L., F. Briones, Jr., S. Brisbay, C. J. Logothetis, and T. J. McDonnell. 1998. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene 17: 2889-2899.
15. Adams, I., V. J. Palombella, E. A. Sausville, J. Johnson, A. Destree, D. D. Lazarus, J. Maas, C. S. Pien, S. Prakash, and P. J. Elliott. 1999. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59: 2615-2622.
16. Teicher, B. A., G. Ara, R. Herbst, V. J. Palombella, and J. Adams. 1999. The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res. 5: 2638-2645.
17. Cusack, J. C., Jr., R. Liu, M. Houston, K. Abendroth, P. J. Elliott, J. Adams, and A. S. Baldwin, Jr. 2001. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-κB inhibition. Cancer Res. 61: 3535-3540.
18. An, W. G., S. G. Hwang, J. B. Trepel, and M. V. Blagosklonny. 2000. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 14: 1276-1283.
19. Mitsiades, N., C. S. Mitsiades, V. Poulaki, D. Chauhan, G. Fanourakis, X. Gu, C. Bailey, M. Joseph, T. A. Libermann, S. P. Treon, et al. 2002. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl. Acad. Sci. USA 99: 14374-14379.
20. Palombella, V. J., E. M. Conner, J. W. Fuseler, A. Destree, J. M. Davis, F. S. Laroux, R. E. Wolf, J. Huang, S. Brand, P. J. Elliott, et al. 1998. Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis. Proc. Natl. Acad. Sci. USA 95: 15671-15676.
21. Russo, S. M., J. E. Tepper, A. S. Baldwin, Jr., R. Liu, J. Adams, P. Elliott, and J. C. Cusack, Jr. 2001. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-κB. Int. J. Radiat. Oncol. Biol. Phys. 50; 183-193.
22. Bold, R. J., S. Virudachalam, and D. J. McConkey. 2001. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J. Surg. Res. 100: 11-17.
23. Hideshima, T., D. Chauhan, T. Hayashi, M. Akiyama, N. Mitsiades, C. Mitsiades, K. Podar, N. C. Munshi, P. G. Richardson, and K. C. Anderson. 2003. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 22: 8386-8393.
24. Dai, Y., M. Rahmani, X. Y. Pei, P. Dent, and S. Grant. 2004. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Ab1-dependent and -independent mechanisms. Blood 104: 509-518.
25. Luo, X., I. Budihardjo, H. Zou, C. Slaughter, and X. Wang. 1998. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-490.
26. + T cells. J. Immunol 173: 7170-7182.
27. Sims, S. H., Y. Cha, M. F. Romine, P. Q. Gao, K. Gottlieb, and A. B. Deisseroth. 1993. A novel interferon-inducible domain: structural and functional analysis of the human interferon regulatory factor 1 gene promoter. Mol. Cell Biol. 13: 690-702.
28. Khan, T., J. A. Hixon, J. K. Stauffer, E. Lincoln, T. C. Back, J. Brenner, S. Lockett, K. Nagashima, D. Powell, and J. M. Wigginton. 2006. Therapeutic modulation of Akt activity and antitumor efficacy of interleukin-12 against orthotopic murine neuroblastoma. J. Natl. Cancer Inst. 98: 190-202.
29. Stokoe, D., L. R. Stephens, T. Copeland, P. R. Gaffney, C. B. Reese, G. F. Painter, A. B. Holmes, F. McCormick, and P. T. Hawkins. 1997. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 277: 567-570.
30. Bellacosa, A., T. O. Chan, N. N. Ahmed, K. Datta, S. Malstrom, D. Stokoe, F. McCormick, J. Feng, and P. Tsichlis. 1998. Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene 17: 313-325.
31. Nesterov, A., X. Lu, M. Johnson, G. J. Miller, Y. Ivashchenko, and A. S. Kraft. 2001. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J. Biol. Chem. 276: 10767-10774.
32. Chen, X., H. Thakkar, F. Tyan, S. Gim, H. Robinson, C. Lee, S. K. Pandey, C. Nwokorie, N. Onwudiwe, and R. K. Srivastava. 2001. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20: 6073-6083.
33. Varela, N., C. Munoz-Pinedo, C. Ruiz-Ruiz, G. Robledo, M. Pedroso, and A. Lopez-Rivas. 2001. Interferon-γ sensitizes human myeloid leukemia cells to death receptor-mediated apoptosis by a pleiotropic mechanism. J. Biol. Chem. 276: 17779-17787.
34. Fulda, S., and K. M. Debatin. 2002. IFN-γ sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene 21: 2295-2308.
35. Aguet, M., Z. Dembic, and G. Merlin, 1988. Molecular cloning and expression of the human interferon-γ receptor. Cell 55: 273-280.
36. Soh, J., R. J. Donnelly, S. Kotenko, T. M. Mariano, J. R. Cook, N. Wang, S. Emanuel, B. Schwartz, T. Miki, and S. Pestka. 1994. Identification and sequence of an accessory factor required for activation of the human interferon-γ receptor. Cell 76: 793-802.
37. Chesler, D. A., and C. S. Reiss. 2002. The role of IFN-γ in immune responses to viral infections of the central nervous system. Cytokine Growth Factor Rev. 13: 441-454.
38. Culliton, B. J. 1992. FDA panel backs interleukin-2. Nature 355: 287.
39. Rosenberg, S. A., M. T. Lotze, J. C. Yang, S. L. Topalian, A. E. Chang, D. J. Schwartzentruber, P. Aebersold, S. Leitman, W. M. Linehan, C. A. Seipp, and, 1993. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst. 85: 622-632.
40. Kuzmits, R., E. M. Kokoschka, M. Micksche, H. Ludwig, and R. Flener. 1985. Phase II results with recombinant interferons: renal cell carcinoma and malignant melanoma. Oncology 42(Suppl. 1): 26-32.
41. Gollob, J. A., J. W. Mier, K. Veenstra, D. F. McDermott, D. Clancy, M. Clancy, and M. B. Atkins. 2000. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-γ induction is associated with clinical response. Clin. Cancer Res. 6: 1678-1692.
42. Motzer, R. J., A. Rakhit, L. H. Schwartz, T. Olencki, T. M. Malone, K. Sandstrom, R. Nadeau, H. Parmar, and R. Bukowski. 1998. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin. Cancer Res. 4: 1183-1191.
43. Robertson, M. J., J. Mier, T. Logan, H. Koon, J. Weisenbach, S. Roberts, C. Oei, L. Kirby, S. Kathman, and L. Pandite. 2004. Tolerabilily and antitumor activity of recombinant human IL-18 (rhIL-18) administered as five daily intravenous infusions in patients with solid tumors. J. Clin. Oncol. 22: 2553.
44. Rosenberg, S. A., J. J. Mule, P. J. Spiess, C. M. Reichert, and S. L. Schwartz. 1985. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J. Exp. Med. 161: 1169-1188.
45. Nastala, C. L., H. D. Edington, T. G. McKinney, H. Tahara, M. A. Nalesnik, M. J. Brunda, M. K. Gately, S. F. Wolf, R. D. Schreiber, W. J. Storkus, and. 1994. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol 153: 1697-1706.
46. Wigginton, J. M., K. L. Komschlies, T. C. Back, J. L. Franco, M. J. Brunda, and R. H. Wiltrout. 1996. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J. Natl. Cancer Inst. 88: 38-43.
47. Wigginton, J. M., J.-K. Lee, T. A. Wiltrout, W. G. Alvord, J. A. Hixon, J. Subleski, T. C. Back, and R. H. Wiltrout. 2002. Synergistic engagement of an ineffective endogenous antitumor immune response and induction of IFN-γ and FAS-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2. J. Immunol 169: 4467-4474.
48. Coughlin, C. M., K. E. Salhany, M. S. Gee, D. C. LaTemple, S. Kotenko, X. Ma, G. Gri, M. Wysocka, J. E. Kim, L. Liu, et al. 1998. Tumor cell responses to IFN-γ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9: 25-34.
49. Brunda, M. J., L. Luistro, J. A. Hendrzak, M. Fountoulakis, G. Garotta, and M. K. Gately. 1995. Role of interferon-γ in mediating the antitumor efficacy of interleukin-12. J. Immunother. Emphasis. Tumor Immunol. 17: 71-77.
50. Wigginton, J. M., E. Gruys, L. Geiselhart, J. Subleski, K. L. Komschlies, J. W. Park, T. A. Wiltrout, K. Nagashima, T. C. Back, and R. H. Wiltrout. 2001. IFN-γ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J. Clin. Invest. 108: 51-62.
51. Sayers, T. J., A. D. Brooks, J. K. Lee, R. G. Fenton, K. L. Komschlies, J. M. Wigginton, R. Winkler-Pickett, and R. H. Wiltrout. 1998. Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells. J. Immunol 161: 3957-3965.
52. + leukocytes and Fas/FasL interactions to induce apoptosis following interleukin-12 gene therapy in a metastatic model of prostate cancer. Hum. Gene Ther. 12: 1485-1498.
53. Smyth, M. J., E. Cretney, K. Takeda, R. H. Wiltrout, L. M. Sedger, N. Kayagaki, H. Yagita, and K. Okumura. 2001. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to Interferon γ-dependent natural killer cell protection from tumor metastasis. J. Exp. Med. 193: 661-670.
54. Blay, J. Y., M. C. Favrot, S. Negrier, V. Combaret, S. Chouaib, A. Mercatello, P. Kaemmerlen, C. R. Franks, and T. Philip. 1990. Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor. Cancer Res. 50: 2371-2374.
55. Breitschopf, K., A. M. Zeiher, and S. Dimmeler. 2000. Ubiquitin-mediated degradation of the proapoptotic active form of bid: a functional consequence on apoptosis induction. J. Biol. Chem. 275: 21648-21652.
56. Williams, S., C. Pettaway, R. Song, C. Papandreou, C. Logothetis, and D. J. McConkey. 2003. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol. Cancer Ther. 1: 835-843.
57. Blaney, S. M., M. Bernstein, K. Neville, J. Ginsberg, B. Kitchen, T. Horton, S. L. Berg, M. Krailo, and P. C. Adamson. 2004. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J. Clin. Oncol. 22: 4752-4757.
58. Sayers, T. J., A. D. Brooks, C. Y. Koh, W. Ma, N. Seki, A. Raziuddin, B. R. Blazar, X. Zhang, P. J. Elliott, and W. J. Murphy. 2003. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 102: 303-310.